KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Tax Provisions (2016 - 2025)

Historic Tax Provisions for BeOne Medicines (ONC) over the last 10 years, with Q3 2025 value amounting to $22.3 million.

  • BeOne Medicines' Tax Provisions fell 313.72% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.7 million, marking a year-over-year increase of 8330.0%. This contributed to the annual value of $111.8 million for FY2024, which is 10007.34% up from last year.
  • Per BeOne Medicines' latest filing, its Tax Provisions stood at $22.3 million for Q3 2025, which was down 313.72% from $5.2 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Tax Provisions high stood at $66.5 million for Q4 2024, and its period low was -$15.4 million during Q4 2021.
  • Over the past 5 years, BeOne Medicines' median Tax Provisions value was $13.7 million (recorded in 2023), while the average stood at $12.8 million.
  • In the last 5 years, BeOne Medicines' Tax Provisions tumbled by 39794.08% in 2021 and then soared by 363956.52% in 2022.
  • BeOne Medicines' Tax Provisions (Quarter) stood at -$15.4 million in 2021, then skyrocketed by 193.59% to $14.4 million in 2022, then rose by 16.78% to $16.8 million in 2023, then surged by 296.46% to $66.5 million in 2024, then tumbled by 66.45% to $22.3 million in 2025.
  • Its Tax Provisions stands at $22.3 million for Q3 2025, versus $5.2 million for Q2 2025 and $19.6 million for Q1 2025.